Innogene Kalbiotech

Focus: Innogene Kalbiotech is a Singapore-based public company focused on biologics, biosimilars, and diagnostics across oncology, cardiovascular, and infectious disease indications. The company operates at a modest scale with a diversified pipeline spanning monoclonal antibodies and specialty therapeutics.

Oncology Cardiovascular Infectious Diseases

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Innogene Kalbiotech

AI assessmentNot Hiring

No open roles listed right now. Follow Innogene Kalbiotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

7 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

0.5M Sodium lactate

Acute Heart Failure

PHASE_2

Clinical Trials (1)

NCT019816550.5M Na Lactate Solution in Acute Heart Failure (AHF)

Phase 2

Help build intelligence for Innogene Kalbiotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified late-stage pipeline with 6 Phase 3 programs providing multiple near-term catalysts in oncology (Nimotuzumab, Racotumomab, RTXM83) and cardiovascular/emergency medicine (hypertonic lactate formulations)
Biologics and biosimilars focus offers exposure to high-margin, defensible therapeutic modalities with strong IP trajectories in growing disease areas
Public company status with Asia-Pacific headquarters provides geographic stability and potential for rapid growth in underserved Asian markets

Watch Out For

Zero active job openings signal either a hiring freeze, organizational stability at current headcount, or limited expansion—career mobility and role variety may be constrained
Lack of published financials, R&D intensity data, and revenue concentration metrics limits transparency on company health, runway, and strategic priorities for prospective employees
No recent news, FDA warnings, or hiring department breakdown provided—absence of communication may indicate limited investor relations activity or media visibility

Generated by Claude from Innogene Kalbiotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Nimotuzumab

Head and Neck Cancer

PHASE_2

Clinical Trials (1)

NCT00702481Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer

Phase 2

Hypertonic lactate

Low Cardiac Output

PHASE_3

Clinical Trials (1)

NCT00529711The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients

Phase 3

Racotumomab

NSCLC

PHASE_3

Clinical Trials (1)

NCT01460472Immunotherapy With Racotumomab in Advanced Lung Cancer

Phase 3

Hyperosmolar sodium lactate

Hemorrhagic Shock

PHASE_3

Clinical Trials (1)

NCT01433276Efficacy, Safety of Solution Containing Hyperosmolar Sodium Lactate Infusion for Resuscitation of Patients With Hemorrhagic Shock

Phase 3

Hypertonic sodium lactate

Dengue Shock Syndrome

PHASE_3

Clinical Trials (1)

NCT00966628Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS)

Phase 3

Nimotuzumab

Carcinoma, Squamous Cell of Head and Neck

PHASE_3

Clinical Trials (1)

NCT00957086Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer

Phase 3

Hypertonic lactate

Low Cardiac Output

PHASE_3

Clinical Trials (1)

NCT00529490Efficacy, Safety of Hypertonic Lactate Soln. as Fluid Resuscitation Compared With Ringer's Lactate in Post-CABG Pats